 |
 |
 |
 |
 |
Subject: Neurotransmitter Abnormalities in ET Brain, SSRI Treatment in Model of PD (PD Congress 2001) Date: 7/30/2001 E-MOVE reports from the 14th International Congress on Parkinson's Disease, Helsinki July 28-Aug 1. Poster and Platform session numbers refer to those in the abstract book, published in Parkinsonism and Related Disorders 2001;7(Supplement).1. Biochemical studies of essential tremor brain AH Rajput, O Hornykiewicz, Y Deng, S Birdi, H Miyashita, R Macaulay P-MO-022 Noradrenaline is elevated in specific brain regions in essential tremor, according to this report. Brains from 3 ET patients and three matched controls were biochemically analyzed by a blinded investigator. Compared to controls, ET patients had elevated noradrenaline in the locus ceruleus (approx. five-fold), the dentate nucleus (130-fold), and the cerebellar cortex (approximately two-fold), with similar levels in the red nucleus. The authors note these findings correlate with increased activity in brainstem and cerebellum as seen in PET studies, and the effectiveness of beta-adrenergic blockers in ET treatment. 2. Fluoxetine reduces l-dopa-derived extracellular dopamine in the rat striatum with nigrostriatal denervation H Yamato, Kannari, H Shen, T Suda, M Matsunaga P-MO-024 Aggravation of parkinsonism by selective serotonin reuptake inhibitors is likely due to reduction of extracellular dopamine, according to this study. Rats with 6-OHDA lesions received intraperitoneal fluoxetine followed by levodopa. Compared to rats not receiving fluoxetine, treated rats had a 59% reduction in extracellular striatal dopamine as determined by microdialysis (p<0.01), "suggesting that fluoxetine reduces concentrations of extracellular dopamine by activating 5-HT1A receptors on serotinergic neurons," the authors concluded. --- Funding for E-MOVE meeting reports is provided in part by unrestricted educational grants from Allergan Inc., Elan Pharmaceuticals, and Pharmacia Corporation. E-MOVE Editor: Richard Robinson, NASW, WE MOVE
|
|
| All contents copyright © WE MOVE 2010. This page last modified 2/25/2009. | |